Bedia Samanci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bedia Samanci has a total of 382 co-authors. Here are the top co-authors by number of shared publications:
- Başar Bilgiç
Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
12 shared publications - Hakan Gurvit
Department of Neurology, Behavioral Neurology and Movement Disorders Unit, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
10 shared publications - Hasmet Ayhan Hanagasi
Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine Istanbul University Istanbul Turkey
7 shared publications Hakan Gurvit
Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine Istanbul University Istanbul Turkey
5 shared publicationsBasar Bilgic
Behavioral Neurology and Movement Disorders Unit, Department of Neurology, Istanbul Faculty of Medicine Istanbul University Istanbul Turkey
4 shared publicationsBaşar Bilgiç
Istanbul Faculty of Medicine, Department of Neurology, Behavioral Neurology and Movement Disorders Unit Istanbul University Istanbul Türkiye
4 shared publications
Latest Publications
- 24 September 2026
- Published by Maastricht University
Parkinson's disease and the habenula
- 1 September 2026
- Published by Wiley in Movement Disorders Clinical Practice
Preoperative Glymphatic Asymmetry Is Associated with Motor Outcomes Following STN ‐ DBS in Parkinson's Disease
Background: Interindividual variability in motor outcomes after subthalamic nucleus deep brain stimulation (STN‐DBS) in Parkinson's disease (PD) remains incompletely understood. Glymphatic‐related imaging abnormalities have been reported in PD, but their relevance to neuromodulation response is unclear. Objectives: To investigate whether preoperative glymphatic function, assessed using the Diffusion Tensor Imaging along the Perivascular Space (DTI‐ALPS) index, is associated with motor outcomes after STN‐DBS and whether hemispheric asymmetry provides additional explanatory value. Methods: We retrospectively evaluated 74 advanced PD patients undergoing bilateral STN‐DBS with ≥6 months follow‐up. Preoperative assessment included 3 T MRI‐derived ALPS measures, Fazekas score, perivascular space burden, MDS‐UPDRS‐III, levodopa responsiveness, and metabolic markers. Primary outcome was percentage motor improvement at follow‐up. Multivariable regression models assessed ALPS associations after adjustment for levodopa responsiveness and measured clinical covariates. Results: Lower ALPS asymmetry index (AI) was independently associated with greater percentage motor improvement (standardized β = −0.508, p < 0.001), while greater preoperative levodopa responsiveness was also associated with improvement ( β = 0.740, p < 0.001). Lower ALPS‐AI was additionally associated with axial motor improvement and responder status at both ≥50% and ≥ 33% thresholds. All four principal levodopa‐adjusted ALPS‐AI associations remained significant after Benjamini‐Hochberg correction (all pFDR≤0.0069). Mean ALPS index, Fazekas score, and perivascular space burden were not associated with motor outcomes. Conclusions: Preoperative glymphatic asymmetry was associated with motor outcomes after STN‐DBS independently of levodopa responsiveness and measured clinical covariates. ALPS‐derived asymmetry may capture outcome variability not reflected by conventional imaging, although prospective validation and evaluation alongside lead localization, stimulation parameters, and programming factors are required.
- 1 September 2026
- Published by Wiley in Movement Disorders Clinical Practice
Preoperative Glymphatic Asymmetry Is Associated with Motor Outcomes Following STN ‐ DBS in Parkinson's Disease
Background: Interindividual variability in motor outcomes after subthalamic nucleus deep brain stimulation (STN‐DBS) in Parkinson's disease (PD) remains incompletely understood. Glymphatic‐related imaging abnormalities have been reported in PD, but their relevance to neuromodulation response is unclear. Objectives: To investigate whether preoperative glymphatic function, assessed using the Diffusion Tensor Imaging along the Perivascular Space (DTI‐ALPS) index, is associated with motor outcomes after STN‐DBS and whether hemispheric asymmetry provides additional explanatory value. Methods: We retrospectively evaluated 74 advanced PD patients undergoing bilateral STN‐DBS with ≥6 months follow‐up. Preoperative assessment included 3 T MRI‐derived ALPS measures, Fazekas score, perivascular space burden, MDS‐UPDRS‐III, levodopa responsiveness, and metabolic markers. Primary outcome was percentage motor improvement at follow‐up. Multivariable regression models assessed ALPS associations after adjustment for levodopa responsiveness and measured clinical covariates. Results: Lower ALPS asymmetry index (AI) was independently associated with greater percentage motor improvement (standardized β = −0.508, p < 0.001), while greater preoperative levodopa responsiveness was also associated with improvement ( β = 0.740, p < 0.001). Lower ALPS‐AI was additionally associated with axial motor improvement and responder status at both ≥50% and ≥ 33% thresholds. All four principal levodopa‐adjusted ALPS‐AI associations remained significant after Benjamini‐Hochberg correction (all pFDR≤0.0069). Mean ALPS index, Fazekas score, and perivascular space burden were not associated with motor outcomes. Conclusions: Preoperative glymphatic asymmetry was associated with motor outcomes after STN‐DBS independently of levodopa responsiveness and measured clinical covariates. ALPS‐derived asymmetry may capture outcome variability not reflected by conventional imaging, although prospective validation and evaluation alongside lead localization, stimulation parameters, and programming factors are required.
- 5 August 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (8) , 680
The glymphatic system and Parkinson’s disease: a narrative review
- 5 August 2026
- Published by Springer Nature in Neurological Sciences
- Vol. 47 (8) , 680
The glymphatic system and Parkinson’s disease: a narrative review
- 22 July 2026
- Published by Wiley in Movement Disorders Clinical Practice
Attitudes in Patients With Prodromal and Overt α ‐Synucleinopathy Toward Risk Disclosure: A Nationwide Registry
Background: Identification of individuals at increased risk for synucleinopathies is becoming more feasible with advances in biomarkers. However, the ethical and practical aspects of communicating disease risk remain unresolved, particularly across diagnostic groups and cultural contexts. Objectives: We aimed to evaluate attitudes toward disclosure of future synucleinopathy risk among individuals with isolated/idiopathic REM sleep behavior disorder (iRBD), as well as in individuals who developed Parkinson's disease (PD), or multiple system atrophy (MSA), in a large non‐Western registry. Methods: This nationwide survey study included participants from 28 movement disorders and sleep centers across Türkiye. Questionnaires assessing attitudes toward risk disclosure, additional testing, and clinical trial participation were administered face‐to‐face. Responses were analyzed using contingency tables and regression models. Results are reported following the Consensus‐Based Checklist for Reporting of Survey Studies (CROSS) guideline. Results: Among 1385 participants (1039 PD, 107 MSA, 239 iRBD), individuals with iRBD showed the highest support for risk disclosure (88.3%), exceeding PD (64.4%) and MSA (51.9%). Approval declined modestly (3–8%) when framed within the absence of disease‐modifying treatment. iRBD participants were more willing for additional testing but less willing to join clinical trials (31.8%) than PD (45.3%) or MSA (48%). MSA patients expressed the greatest concern about psychological impact. Male sex had more favorable views on disclosure and trial participation, while younger and better‐educated participants favored additional testing. Conclusions: Attitudes toward risk disclosure differ markedly across the synucleinopathy spectrum and demographic characteristics. Culturally informed and diagnosis‐specific disclosure strategies will be essential for trial recruitment and patient‐centered care.
- 22 July 2026
- Published by Wiley in Movement Disorders Clinical Practice
Attitudes in Patients With Prodromal and Overt α ‐Synucleinopathy Toward Risk Disclosure: A Nationwide Registry
Background: Identification of individuals at increased risk for synucleinopathies is becoming more feasible with advances in biomarkers. However, the ethical and practical aspects of communicating disease risk remain unresolved, particularly across diagnostic groups and cultural contexts. Objectives: We aimed to evaluate attitudes toward disclosure of future synucleinopathy risk among individuals with isolated/idiopathic REM sleep behavior disorder (iRBD), as well as in individuals who developed Parkinson's disease (PD), or multiple system atrophy (MSA), in a large non‐Western registry. Methods: This nationwide survey study included participants from 28 movement disorders and sleep centers across Türkiye. Questionnaires assessing attitudes toward risk disclosure, additional testing, and clinical trial participation were administered face‐to‐face. Responses were analyzed using contingency tables and regression models. Results are reported following the Consensus‐Based Checklist for Reporting of Survey Studies (CROSS) guideline. Results: Among 1385 participants (1039 PD, 107 MSA, 239 iRBD), individuals with iRBD showed the highest support for risk disclosure (88.3%), exceeding PD (64.4%) and MSA (51.9%). Approval declined modestly (3–8%) when framed within the absence of disease‐modifying treatment. iRBD participants were more willing for additional testing but less willing to join clinical trials (31.8%) than PD (45.3%) or MSA (48%). MSA patients expressed the greatest concern about psychological impact. Male sex had more favorable views on disclosure and trial participation, while younger and better‐educated participants favored additional testing. Conclusions: Attitudes toward risk disclosure differ markedly across the synucleinopathy spectrum and demographic characteristics. Culturally informed and diagnosis‐specific disclosure strategies will be essential for trial recruitment and patient‐centered care.
- Open Access
- 20 July 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
Stage‐Dependent β‐Synuclein Links MRI and Cognitive Decline in Alzheimer's Disease
Objective: Synaptic degeneration drives cognitive decline in Alzheimer's disease (AD), but synaptic biomarkers are scarce. Brain‐enriched β‐synuclein emerged as a synaptic damage marker. We investigated its diagnostic, prognostic, and structural correlates across the AD continuum. Methods: In a tertiary‐center cohort ( n = 306), CSF β‐synuclein was measured. Cognitively unimpaired (CU), AD‐MCI, AD dementia (ADD), and non‐AD (FTD, PD, DLB, others) groups were included. ANCOVA compared groups (age/sex adjusted); ROC assessed diagnostic performance. Multivariable regression examined 2‐year MMSE decline associations. Voxel‐wise interaction models evaluated β‐synuclein–gray matter volume (GMV) relationships. Results: CSF β‐synuclein differed across groups ( p < 0.001), with highest levels observed in AD‐MCI and lower levels in ADD. AD‐MCI levels exceeded CU/ADD. AD‐MCI versus CU AUC was 0.874. Baseline β‐synuclein predicted greater MMSE decline in AD‐MCI ( β = 0.72, p < 0.001) and ADD ( β = 0.47, p = 0.017). Voxel‐wise analyses revealed stage‐dependent β‐synuclein–GMV reversals in precentral and temporoparietal regions. Conclusion: CSF β‐synuclein shows a stage‐dependent pattern across the AD continuum, predicts cognitive decline, and dynamic structural coupling. It supports β‐synuclein as a relevant synaptic biomarker in AD.
- 20 July 2026
- Published by Wiley in Annals of Clinical and Translational Neurology
Open AccessStage‐Dependent β‐Synuclein Links MRI and Cognitive Decline in Alzheimer's Disease
Objective: Synaptic degeneration drives cognitive decline in Alzheimer's disease (AD), but synaptic biomarkers are scarce. Brain‐enriched β‐synuclein emerged as a synaptic damage marker. We investigated its diagnostic, prognostic, and structural correlates across the AD continuum. Methods: In a tertiary‐center cohort ( n = 306), CSF β‐synuclein was measured. Cognitively unimpaired (CU), AD‐MCI, AD dementia (ADD), and non‐AD (FTD, PD, DLB, others) groups were included. ANCOVA compared groups (age/sex adjusted); ROC assessed diagnostic performance. Multivariable regression examined 2‐year MMSE decline associations. Voxel‐wise interaction models evaluated β‐synuclein–gray matter volume (GMV) relationships. Results: CSF β‐synuclein differed across groups ( p < 0.001), with highest levels observed in AD‐MCI and lower levels in ADD. AD‐MCI levels exceeded CU/ADD. AD‐MCI versus CU AUC was 0.874. Baseline β‐synuclein predicted greater MMSE decline in AD‐MCI ( β = 0.72, p < 0.001) and ADD ( β = 0.47, p = 0.017). Voxel‐wise analyses revealed stage‐dependent β‐synuclein–GMV reversals in precentral and temporoparietal regions. Conclusion: CSF β‐synuclein shows a stage‐dependent pattern across the AD continuum, predicts cognitive decline, and dynamic structural coupling. It supports β‐synuclein as a relevant synaptic biomarker in AD.
- 21 May 2026
- Published by Istanbul University in İstanbul Journal of Pharmacy
- Vol. 56 (1) , 27-35
Evaluation of Drug-Related Problems in Inpatients at the Neurology Department of Tertiary University Hospital in Türkiye
Background and Aims: The prevalence and characteristics of drug-related problems (DRPs) and factors associated with the occurrence of DRPs in inpatients in the neurology department in Türkiye remain unknown. This study aimed to determine the characteristics of DRPs and to identify drug-drug interactions (DDIs) in the neurology department of a tertiary university hospital in Türkiye.Methods: This prospective study with clinical pharmacist (CP) intervention was conducted at the Department of Neurology, Istanbul University Istanbul Faculty of Medicine Hospital, between December 2023 and June 2024 by clinical pharmacy residents (CPRs). The characteristics of DRPs were categorised using the Pharmaceutical Care Network Europe (PCNE) DRP classification tool V9.1, and DDIs were identified using Micromedex® drug interaction software.Results: A total of 106 DRPs were detected in 63 inpatients, an average of 1.68 DRPs per patient. Using the PCNE classification system, treatment safety (P2) was identified as the most common type of DRP (69; 65.09%), whereas drug selection (C1) was the primary cause (94; 83.93%). CPRs provided a total of 120 interventions, and most interventions occurred at the prescriber level (I1) (107; 89.17%), and all were accepted. A total of 205 DDIs were detected (59/63;93.65%), most of which were classified as major (136;66.34%).Conclusions: This study demonstrates that DRPs can occur at any stage of the prescribing process and are common among inpatients in the neurology department in Türkiye. These findings may encourage further research on the roles of CPs in neurology departments using controlled study designs.
- 21 May 2026
- Published by Istanbul University in İstanbul Journal of Pharmacy
- Vol. 56 (1) , 27-35
Evaluation of Drug-Related Problems in Inpatients at the Neurology Department of Tertiary University Hospital in Türkiye
Background and Aims: The prevalence and characteristics of drug-related problems (DRPs) and factors associated with the occurrence of DRPs in inpatients in the neurology department in Türkiye remain unknown. This study aimed to determine the characteristics of DRPs and to identify drug-drug interactions (DDIs) in the neurology department of a tertiary university hospital in Türkiye.Methods: This prospective study with clinical pharmacist (CP) intervention was conducted at the Department of Neurology, Istanbul University Istanbul Faculty of Medicine Hospital, between December 2023 and June 2024 by clinical pharmacy residents (CPRs). The characteristics of DRPs were categorised using the Pharmaceutical Care Network Europe (PCNE) DRP classification tool V9.1, and DDIs were identified using Micromedex® drug interaction software.Results: A total of 106 DRPs were detected in 63 inpatients, an average of 1.68 DRPs per patient. Using the PCNE classification system, treatment safety (P2) was identified as the most common type of DRP (69; 65.09%), whereas drug selection (C1) was the primary cause (94; 83.93%). CPRs provided a total of 120 interventions, and most interventions occurred at the prescriber level (I1) (107; 89.17%), and all were accepted. A total of 205 DDIs were detected (59/63;93.65%), most of which were classified as major (136;66.34%).Conclusions: This study demonstrates that DRPs can occur at any stage of the prescribing process and are common among inpatients in the neurology department in Türkiye. These findings may encourage further research on the roles of CPs in neurology departments using controlled study designs.
- Open Access
- 15 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Variants in the proteasome regulator PSMF1 cause a phenotypic spectrum from parkinsonism to perinatal lethality
Dissecting biological pathways highlighted by Mendelian gene discovery has provided critical insights into the pathogenesis of Parkinson’s disease (PD) and neurodegeneration. This approach ultimately catalyzes the identification of potential biomarkers and therapeutic targets. Here we identify PSMF1 as a gene implicated in parkinsonism and childhood neurodegeneration. We find that biallelic PSMF1 missense and loss-of-function variants co-segregate with phenotypes from early-onset PD to perinatal lethality with neurological manifestations across 18 pedigrees with 25 affected subjects, showing clear genotype-phenotype correlation. PSMF1 encodes the proteasome regulator PSMF1/hPI31, a highly conserved, ubiquitously expressed partner of the 20S proteasome and neurodegeneration-associated F-box-O 7 and valosin-containing proteins. We demonstrate that PSMF1 variants may affect proteasomal abundance and assembly, and are associated with alterations of mitochondrial membrane potential, respiration, dynamics and mitophagy in patient-derived fibroblasts. Furthermore, Drosophila and mouse models of PI31 loss of function exhibit age-dependent motor impairment, as well as brain-wide mitochondrial membrane depolarization and dopaminergic neurodegeneration in aged flies, and diffuse gliosis in mice. Collectively, our findings unequivocally link defective PSMF1/hPI31 to early-onset parkinsonism and neurodegeneration, and suggest proteasomal and mitochondrial dysfunction as pathogenic contributors.
- 15 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessVariants in the proteasome regulator PSMF1 cause a phenotypic spectrum from parkinsonism to perinatal lethality
Dissecting biological pathways highlighted by Mendelian gene discovery has provided critical insights into the pathogenesis of Parkinson’s disease (PD) and neurodegeneration. This approach ultimately catalyzes the identification of potential biomarkers and therapeutic targets. Here we identify PSMF1 as a gene implicated in parkinsonism and childhood neurodegeneration. We find that biallelic PSMF1 missense and loss-of-function variants co-segregate with phenotypes from early-onset PD to perinatal lethality with neurological manifestations across 18 pedigrees with 25 affected subjects, showing clear genotype-phenotype correlation. PSMF1 encodes the proteasome regulator PSMF1/hPI31, a highly conserved, ubiquitously expressed partner of the 20S proteasome and neurodegeneration-associated F-box-O 7 and valosin-containing proteins. We demonstrate that PSMF1 variants may affect proteasomal abundance and assembly, and are associated with alterations of mitochondrial membrane potential, respiration, dynamics and mitophagy in patient-derived fibroblasts. Furthermore, Drosophila and mouse models of PI31 loss of function exhibit age-dependent motor impairment, as well as brain-wide mitochondrial membrane depolarization and dopaminergic neurodegeneration in aged flies, and diffuse gliosis in mice. Collectively, our findings unequivocally link defective PSMF1/hPI31 to early-onset parkinsonism and neurodegeneration, and suggest proteasomal and mitochondrial dysfunction as pathogenic contributors.
- Open Access
- 31 January 2026
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 19 (1) , 98-101
Uncommon Presentation of Subacute Sclerosing Panencephalitis: Two Cases of Rapidly Progressive Parkinsonism
Uncommon Presentation of Subacute Sclerosing Panencephalitis: Two Cases of Rapidly Progressive Parkinsonism
- 31 January 2026
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 19 (1) , 98-101
Open AccessUncommon Presentation of Subacute Sclerosing Panencephalitis: Two Cases of Rapidly Progressive Parkinsonism
Uncommon Presentation of Subacute Sclerosing Panencephalitis: Two Cases of Rapidly Progressive Parkinsonism
- Open Access
- 12 December 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 523
Clinical recognition of frontotemporal dementia with right temporal predominance: a consensus statement from the International Working Group
Accurate diagnosis of frontotemporal dementia (FTD) with right anterior temporal lobe (RATL) predominance remains challenging due to lack of clinical characterization, and standardized terminology. The recent research of the International Working Group (IWG) identified common symptoms but also unveiled broad terminologies lacking precision and operationalization, with risk of misdiagnoses, inappropriate referrals and poor clinical management. Based on the published evidence (91267 articles screened) and expert opinion (105 FTD specialists across 52 centers) by using the nominal group technique, the IWG delineates three primary domains of impairment causing behavioral, memory and language problems: (i) multimodal knowledge of non-verbal information including people, living beings, landmarks, flavors/odors, sounds, bodily sensations, emotions and social cues; (ii) socioemotional behavior encompassing emotion expression, social response and motivation; and (iii) prioritization for focus on specific interests, hedonic valuation and personal preferences. This study establishes a consensus on clinical profile, phenotypic nomenclature, and future directions to enhance diagnostic precision and therapeutic interventions.
- 12 December 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 523
Open AccessClinical recognition of frontotemporal dementia with right temporal predominance: a consensus statement from the International Working Group
Accurate diagnosis of frontotemporal dementia (FTD) with right anterior temporal lobe (RATL) predominance remains challenging due to lack of clinical characterization, and standardized terminology. The recent research of the International Working Group (IWG) identified common symptoms but also unveiled broad terminologies lacking precision and operationalization, with risk of misdiagnoses, inappropriate referrals and poor clinical management. Based on the published evidence (91267 articles screened) and expert opinion (105 FTD specialists across 52 centers) by using the nominal group technique, the IWG delineates three primary domains of impairment causing behavioral, memory and language problems: (i) multimodal knowledge of non-verbal information including people, living beings, landmarks, flavors/odors, sounds, bodily sensations, emotions and social cues; (ii) socioemotional behavior encompassing emotion expression, social response and motivation; and (iii) prioritization for focus on specific interests, hedonic valuation and personal preferences. This study establishes a consensus on clinical profile, phenotypic nomenclature, and future directions to enhance diagnostic precision and therapeutic interventions.
- 20 November 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 98
The CSF Levels of Mitochondrial Phosphoenolpyruvate Carboxykinase 2 as a Novel Biomarker in Alzheimer’s Disease
Studies have shown that the expression patterns of neurons and glia can be altered by the Aβ fragments. We hypothesized that genes regulated by Aβ-affected transcription factors (TFs) are most impacted by amyloid pathology, leading to significant expression changes. To test this, we focused on three key TFs namely, Jun, Fos, and RELA, and identified 13 common genes they regulate. Given AD-related neurodegeneration disrupts essential cellular processes like mitochondrial function and glucose metabolism, we selected PCK2 as a biomarker candidate from these 13 common genes. The present study included core CSF biomarker validated 154 AD, 41 non-AD MCI patients, and 16 individuals with subjective cognitive impairment. We measured the PCK2 levels in CSF of the cases and controls with ELISA. The PCK2 levels were significantly lower in the CSF of AD cases compared to SCI or non-AD MCI cases. The PCK2 levels of A − individuals were significantly lower than that of A + individuals. Similarly, T − or (N) − individuals exhibit significantly lower levels of CSF PCK2 compared to their + counterparts. Each area under the curve for the ROC analysis of CSF pTau(181)/CSF PCK2 ratio in SCI vs. AD, non-AD MCI vs. AD, A − vs. A + , T − vs. T + and (N) − vs. (N) + were higher than 84%. The sensitivity and specificity of each analysis were at least 76% and 83%; respectively. A positive correlation was determined between CSF PCK2 and Aβ1–42 in AD. PCK2, along with other mitochondrial proteins, could be utilized as a mitochondrial biomarker for neurodegeneration, and PCK2 levels should be investigated in large cohorts for verification.
- 20 November 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 98
The CSF Levels of Mitochondrial Phosphoenolpyruvate Carboxykinase 2 as a Novel Biomarker in Alzheimer’s Disease
Studies have shown that the expression patterns of neurons and glia can be altered by the Aβ fragments. We hypothesized that genes regulated by Aβ-affected transcription factors (TFs) are most impacted by amyloid pathology, leading to significant expression changes. To test this, we focused on three key TFs namely, Jun, Fos, and RELA, and identified 13 common genes they regulate. Given AD-related neurodegeneration disrupts essential cellular processes like mitochondrial function and glucose metabolism, we selected PCK2 as a biomarker candidate from these 13 common genes. The present study included core CSF biomarker validated 154 AD, 41 non-AD MCI patients, and 16 individuals with subjective cognitive impairment. We measured the PCK2 levels in CSF of the cases and controls with ELISA. The PCK2 levels were significantly lower in the CSF of AD cases compared to SCI or non-AD MCI cases. The PCK2 levels of A − individuals were significantly lower than that of A + individuals. Similarly, T − or (N) − individuals exhibit significantly lower levels of CSF PCK2 compared to their + counterparts. Each area under the curve for the ROC analysis of CSF pTau(181)/CSF PCK2 ratio in SCI vs. AD, non-AD MCI vs. AD, A − vs. A + , T − vs. T + and (N) − vs. (N) + were higher than 84%. The sensitivity and specificity of each analysis were at least 76% and 83%; respectively. A positive correlation was determined between CSF PCK2 and Aβ1–42 in AD. PCK2, along with other mitochondrial proteins, could be utilized as a mitochondrial biomarker for neurodegeneration, and PCK2 levels should be investigated in large cohorts for verification.